Physician profile
Shailaja Jamma
NPI 1356584908
$2,724.72
in general payments reported to CMS, 2019-2025
17 companies · $343 in 2025
The $343 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $124 · 2021: $1,094 · 2022: $1,034 · 2023: $35.14 · 2024: $94.54 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $858.15 | 2020-2023 | Xifaxan, Plenvu |
| Abbvie INC. | $373.55 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $305.92 | 2020-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $283.64 | 2021-2022 | |
| Qol Medical, LLC | $251.80 | 2021-2022 | |
| Celltrion USA INC. | $140.08 | 2024-2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $98.16 | 2025 | Zenpep |
| Braintree Laboratories, INC. | $93.87 | 2020-2022 | |
| Janssen Biotech, INC. | $77.43 | 2021 | |
| Celgene Corporation | $58.88 | 2022 | |
| Intra-Sana Laboratories | $43.59 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Ironwood Pharmaceuticals, INC | $31.13 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.08 | 2025 | Entyvio |
| Novo Nordisk INC | $24.02 | 2025 | Wegovy |
| Gilead Sciences, INC. | $20.77 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $20.18 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shailaja Jamma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.